Avandia, Actos Add Black Box; RECORD Leaves Heart Attack Risk Unresolved

FDA is adding a "black box" warning about the risk of congestive heart failure to thiazolidinediones while it continues to evaluate the potential risk of myocardial infarction seen in the class of type 2 diabetes therapies